Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 7/20 | 0.41 |
| ▸ | ULK1 | O75385 | 6/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635999 | 0.86 | JAK3 (0.54) | JAK3FLT3ULK1CHEK1PTK2 | |
| SCHEMBL3286659 | 0.81 | JAK3 (0.43) | JAK3FLT3ULK1CHEK1PTK2 | |
| SCHEMBL3285060 | 0.78 | JAK3 (0.47) | JAK3FLT3CHEK1PTK2CYP1A2 | |
| SCHEMBL1916599 | 0.76 | JAK3 (0.56) | JAK3FLT3ULK1CDK1PTK2 | |
| SCHEMBL1916653 | 0.76 | FLT3 (0.48) | JAK3FLT3CHEK1CDK1PTK2 | |
| SCHEMBL1916419 | 0.76 | JAK3 (0.53) | JAK3ULK1CHEK1PTK2 | |
| SCHEMBL1918411 | 0.74 | JAK3 (0.49) | JAK3ULK1PTK2CYP1A2CNR2 | |
| SCHEMBL3284549 | 0.74 | CHEK1 (0.43) | JAK3ULK1CHEK1CDK1PTK2 | |
| SCHEMBL1917531 | 0.73 | ULK1 (0.52) | JAK3ULK1CDK1PTK2CYP1A2 | |
| SCHEMBL1917888 | 0.73 | JAK3 (0.47) | JAK3FLT3ULK1PTK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | JAK3 1209/4885FLT3 278/4885ULK1 1959/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | JAK3 497/4885FLT3 343/4885ULK1 3079/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | JAK3 1209/4885FLT3 278/4885ULK1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.